Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT01482260
First received: November 26, 2011
Last updated: November 5, 2012
Last verified: November 2012

November 26, 2011
November 5, 2012
December 2011
January 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01482260 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma
Comparative Microarray Analysis of microRNA Expression Profiles in Primary Cutaneous Malignant Melanoma, Cutaneous Malignant Melanoma Metastases and Benign Melanocytic Naevi

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). This study will be an exploratory analysis by miRNA expression profiling using microarrays.

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). With regards to a rapidly growing number of newly discovered miRNA sequences, the availability of up-to-date miRNA expression profiles for primary cutaneous malignant melanoma (PCMM), cutaneous malignant melanoma metastases (CMMM) and benign melanocytic naevi (BMN) is limited. Patients with PCMM, CMMM and BMN are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays. Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

skin biopsy

Non-Probability Sample

Patients with

  • Primary Cutaneous Malignant Melanoma
  • Cutaneous Malignant Melanoma Metastases
  • Benign Melanocytic Naevi
Cutaneous Malignant Melanoma
Procedure: Biopsy
Biopsy
Other Name: n.a.
  • Primary Cutaneous Malignant Melanoma
    Intervention: Procedure: Biopsy
  • Cutaneous Malignant Melanoma Metastases
    Intervention: Procedure: Biopsy
  • Benign Melanocytic Nevi
    Intervention: Procedure: Biopsy
Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA, Altmeyer P, Bechara FG. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2012 Oct 31. [Epub ahead of print]

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
Not Provided
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Primary Cutaneous Malignant Melanoma
  • Cutaneous Malignant Melanoma Metastases
  • Benign Melanocytic Naevi

Exclusion Criteria:

- Other Skin Cancer than Primary Cutaneous Malignant Melanoma

Both
1 Year and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01482260
microRNA5
Yes
Michael Sand, Ruhr University of Bochum
Ruhr University of Bochum
Not Provided
Study Director: Falk G Bechara, PD Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Study Chair: Peter Altmeyer, Prof. Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Ruhr University of Bochum
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP